EPO to Protect Renal Function After Cardiac Surgery. A Phase II Double Blind Randomized Controlled Study. (EPRICS)

NCT01423955 Phase 2 COMPLETED

The purpose of this study is to evaluate the potential of erythropoietin in reducing risk and degree of acute kidney injury after cardiac surgery.

Details

Lead sponsor	Region Skane
Phase	Phase 2
Status	COMPLETED
Enrolment	75
Start date	2011-10
Completion	2013-04

Conditions

• Kidney Failure
• Renal Failure

Interventions

• Erythropoietin zeta
• Placebo

Primary outcomes

• Change in plasma cystatin C measured on day 3 postoperatively. — 3 days postoperatively

Countries

Sweden